scholarly journals The Deconstructed Granuloma: A Complex High-Throughput Drug Screening Platform for the Discovery of Host-Directed Therapeutics Against Tuberculosis

2018 ◽  
Vol 8 ◽  
Author(s):  
Lu Huang ◽  
Nicole L. Kushner ◽  
Monique E. Theriault ◽  
Davide Pisu ◽  
Shumin Tan ◽  
...  
Keyword(s):  
High Throughput ◽  
Drug Screening ◽  
High Throughput Drug Screening ◽  
Screening Platform

Abstract 1619: Personalized medicine: A CLIA-certified high-throughput drug screening platform for ovarian cancer

2018 ◽  
Author(s):  
Hallie A. Swan ◽  
Rachele Rosati ◽  
Caroline Bridgwater ◽  
Michael J. Churchill ◽  
Roland M. Watt ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Personalized Medicine ◽  
High Throughput ◽  
Drug Screening ◽  
High Throughput Drug Screening ◽  
Screening Platform

scholarly journals First person – Alexandra Lubin

Biology Open ◽  
2021 ◽  
Vol 10 (9) ◽  
Keyword(s):  
High Throughput ◽  
Drug Screening ◽  
Early Career ◽  
First Person ◽  
High Throughput Drug Screening ◽  
Research Associate ◽  
University College London ◽  
Postdoctoral Research ◽  
Screening Platform ◽  
Selection Of

ABSTRACT First Person is a series of interviews with the first authors of a selection of papers published in Biology Open, helping early-career researchers promote themselves alongside their papers. Alexandra Lubin is first author on ‘ A versatile, automated and high-throughput drug screening platform for zebrafish embryos’, published in BiO. Alexandra is a postdoctoral research associate in the lab of Elspeth Payne at University College London (UCL), London, UK, investigating high-throughput automated drug screening in live zebrafish to discover novel therapeutics for myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).

High-Throughput Drug Screening of FDA-Approved Cancer Drugs Reveals Novel Therapies for Patients with Chordomas

2019 ◽  
Author(s):  
Philip Tatman ◽  
Anthony Fringuello ◽  
Denise Damek ◽  
Samy Youssef ◽  
Randy Jensn ◽  
...  
Keyword(s):  
High Throughput ◽  
Drug Screening ◽  
Novel Therapies ◽  
Cancer Drugs ◽  
High Throughput Drug Screening

High-Throughput Drug Screening of ECM Deposition Inhibitors for Antifibrotic Drug Discovery

2019 ◽  
Author(s):  
Michael Gerckens ◽  
Hani Alsafadi ◽  
Darcy Wagner ◽  
Katharina Heinzelmann ◽  
Kenji Schorpp ◽  
...  
Keyword(s):  
Drug Discovery ◽  
High Throughput ◽  
Drug Screening ◽  
High Throughput Drug Screening

Therapeutic stratification of acute leukemia using high throughput drug screening

2020 ◽  
Author(s):  
S Bhatia ◽  
H Ahlert ◽  
N Dienstbier ◽  
J Schliehe-Diecks ◽  
M Sönnichsen ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
High Throughput ◽  
Drug Screening ◽  
High Throughput Drug Screening

scholarly journals High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells

2021 ◽  
Vol 11 (7) ◽  
Author(s):  
Ruochen Jia ◽  
Leon Kutzner ◽  
Anna Koren ◽  
Kathrin Runggatscher ◽  
Peter Májek ◽  
...  
Keyword(s):  
High Throughput ◽  
Drug Screening ◽  
Synthetic Lethality ◽  
Myeloproliferative Neoplasms ◽  
Hematopoietic Cells ◽  
Replication Stress ◽  
Phase Cell ◽  
Nuclear Staining ◽  
Wild Type ◽  
High Throughput Drug Screening

AbstractMutations of calreticulin (CALR) are the second most prevalent driver mutations in essential thrombocythemia and primary myelofibrosis. To identify potential targeted therapies for CALR mutated myeloproliferative neoplasms, we searched for small molecules that selectively inhibit the growth of CALR mutated cells using high-throughput drug screening. We investigated 89 172 compounds using isogenic cell lines carrying CALR mutations and identified synthetic lethality with compounds targeting the ATR-CHK1 pathway. The selective inhibitory effect of these compounds was validated in a co-culture assay of CALR mutated and wild-type cells. Of the tested compounds, CHK1 inhibitors potently depleted CALR mutated cells, allowing wild-type cell dominance in the co-culture over time. Neither CALR deficient cells nor JAK2V617F mutated cells showed hypersensitivity to ATR-CHK1 inhibition, thus suggesting specificity for the oncogenic activation by the mutant CALR. CHK1 inhibitors induced replication stress in CALR mutated cells revealed by elevated pan-nuclear staining for γH2AX and hyperphosphorylation of RPA2. This was accompanied by S-phase cell cycle arrest due to incomplete DNA replication. Transcriptomic and phosphoproteomic analyses revealed a replication stress signature caused by oncogenic CALR, suggesting an intrinsic vulnerability to CHK1 perturbation. This study reveals the ATR-CHK1 pathway as a potential therapeutic target in CALR mutated hematopoietic cells.

Sign in / Sign up

Export Citation Format

Share Document